Alobresib + Exemestane + Fulvestrant
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumors and Lymphomas
Conditions
Solid Tumors and Lymphomas
Trial Timeline
Mar 16, 2015 → Oct 11, 2017
NCT ID
NCT02392611About Alobresib + Exemestane + Fulvestrant
Alobresib + Exemestane + Fulvestrant is a phase 1 stage product being developed by Gilead Sciences for Solid Tumors and Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT02392611. Target conditions include Solid Tumors and Lymphomas.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02392611 | Phase 1 | Completed |
Competing Products
20 competing products in Solid Tumors and Lymphomas